Univest
Univest
  • Markets

Nifty Pharma Prediction for Tomorrow, 28 July 2026: Index Surges 1.56 Percent to 25,945.75, a Fresh Monthly High

  • July 27, 2026
  • Posted by: Ankit Jaiswal
  • Category: News
No Comments

Nifty Pharma prediction for tomorrow 28 July 2026: index at 25,945.75, up 1.56 percent Monday, a fresh monthly high. Support 25,640. Resistance 25,970.

Nifty Pharma closed at 25,945.75 on Monday, up 397.60 points or 1.56 percent, a fresh high for the month that decisively confirms Thursday’s own more contained decline was genuine stabilisation rather than continued weakness tied to Dr Reddy’s stock-specific concerns.

Ankit Jaiswal, Senior Research Analyst at Univest, notes that the Nifty Pharma prediction for tomorrow now reflects full confirmation of the deceleration pattern flagged Thursday, since the sector’s own sharp Monday rebound, well beyond what the broader market’s own relief rally alone would explain, suggests genuine sector-specific buying interest has returned.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Nifty Pharma Recap
  • Nifty Pharma Prediction For Tomorrow: Trend and Key Levels
  • Full Confirmation of the Stabilisation Pattern
  • Key Triggers for the Nifty Pharma Prediction For Tomorrow
  • Stocks to Watch in the Pharma Sector
  • Risks to the Nifty Pharma Prediction For Tomorrow
  • Conclusion
  • FAQs
    • What is the Nifty Pharma prediction for tomorrow, 28 July 2026?
    • Which analyst gave the Nifty Pharma prediction for tomorrow?
    • Did pharma’s stabilisation from Thursday hold?
    • Is Monday’s rally purely tied to the broader relief rally?

Nifty Pharma Recap

The index opened at 25,639.35, touched a high of 25,972.85 and a low of 25,592.40 before closing at 25,945.75, near the top of its range. This decisive rebound, the sector’s sharpest single-day gain in weeks, confirms Thursday’s own more contained pullback was indeed the sector finding its footing after Dr Reddy’s stock-specific weakness.

Nifty Pharma Prediction For Tomorrow: Trend and Key Levels

Trend: Bullish Above 25,640

Support 1 25,640
Support 2 25,400
Resistance 1 25,970
Resistance 2 26,150

Ankit Jaiswal flags 25,640 as the key support, with 25,970 as the near-term resistance, matching Monday’s high. A close above 26,150 would confirm the sector’s rebound has further room, while a break under 25,400 would suggest fresh caution has resurfaced.

Full Confirmation of the Stabilisation Pattern

The US and Iran paused strikes over the weekend after two weeks of attacks, a fragile de-escalation rather than a confirmed ceasefire, since Iran and Oman held talks on the shipping route but actual traffic through the Strait of Hormuz remains unchanged. Crude oil tumbled roughly 8 percent and India VIX plunged nearly 10 percent, its sharpest single-day drop of the entire crisis. Nifty and Sensex snapped their five-session losing streak, with DIIs buying heavily even as FIIs remained net sellers. IT stocks led the rally, boosted also by strong US major ServiceNow’s own earnings beat. Pharma remains largely insulated from these geopolitical and earnings-driven cues directly, but the sector’s own decisive Monday rebound, well beyond what broader market relief alone would explain, confirms its recent stock-specific weakness has genuinely passed.

Key Triggers for the Nifty Pharma Prediction For Tomorrow

  • Whether the fresh high extends further: Would confirm the sector’s rebound has genuine, continued momentum.
  • Dr Reddy’s own recovery: Worth tracking directly for confirmation its earlier stock-specific weakness has fully resolved.
  • HDFC Bank fell a further 0.44 percent to Rs 739.55 on Monday, its fifth straight decline, the sole major laggard even as the broader market staged a sharp relief rally.

Talk to a SEBI Registered Investment Advisor Before Your Next Trade

Stocks to Watch in the Pharma Sector

Key pharma constituents worth tracking alongside the broader sector outlook.

  • Sun Pharma: Sun Pharma is a sector bellwether worth tracking for stock-level signals within the pharma space.
  • Nifty Healthcare: The closely related healthcare index moved in a similarly strong fashion on Monday.

Risks to the Nifty Pharma Prediction For Tomorrow

  • Profit booking: After a sharp rebound to a fresh monthly high, some consolidation would not be unusual.
  • US regulatory setback: Any adverse FDA decision would compound renewed sector-specific weakness.
  • A resumption of hostilities: Would test the durability of Monday’s broad relief rally.

Download the Univest iOS App or Univest Android App to track live Nifty Pharma levels and get daily research from SEBI registered analysts.

Conclusion

The Nifty Pharma prediction for tomorrow, 28 July 2026, is bullish above 25,640, after the sector’s decisive Monday rebound confirmed Thursday’s own deceleration was genuine stabilisation. Ankit Jaiswal flags 25,640 as the key support in the Nifty Pharma prediction for tomorrow, with whether this fresh high extends further the key signal heading into Tuesday.

Univest is a SEBI Registered Research Analyst (INH000013776) and Investment Adviser (INA000017639). This article is for educational and informational purposes only and should not be construed as investment advice. Investments in securities market are subject to market risks, read all the related documents carefully before investing. Past performance is not indicative of future returns. Please consult your financial advisor before making any investment decisions.

FAQs

What is the Nifty Pharma prediction for tomorrow, 28 July 2026?

Ans. The Nifty Pharma prediction for tomorrow, 28 July 2026, is bullish above 25,640. The index closed at 25,945.75 on Monday, up 1.56 percent, a fresh monthly high.

Which analyst gave the Nifty Pharma prediction for tomorrow?

Ans. Ankit Jaiswal, Senior Research Analyst at Univest, has shared the Nifty Pharma prediction for tomorrow, flagging 25,640 as the key support level.

Did pharma’s stabilisation from Thursday hold?

Ans. Yes, fully; the Nifty Pharma prediction for tomorrow notes Monday’s decisive rebound, the sector’s sharpest gain in weeks, confirms Thursday’s own more contained decline was genuine stabilisation after Dr Reddy’s earlier stock-specific weakness.

Is Monday’s rally purely tied to the broader relief rally?

Ans. Not entirely; the Nifty Pharma prediction for tomorrow notes the sector’s own gain went well beyond what broader market relief alone would explain, suggesting genuine sector-specific buying interest has also returned.



Prediction for tomorrow
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply